IL13Rα2-CD3 BTE

IL13Rα2-CD3 BTE is a **bispecific T-cell engager** designed to target tumors expressing interleukin-13 receptor subunit alpha-2 (IL13Rα2). It consists of a fusion between an anti-IL13Rα2 single-chain variable fragment and an anti-CD3 single-chain variable fragment, connected by a GS linker. The drug acts by **bringing T cells into close proximity with IL13Rα2-expressing tumor cells**, thereby activating T cells via the CD3 pathway and directing their cytotoxic activity to the tumor cell. Preclinical studies demonstrate that IL13Rα2-CD3 BTE induces specific, dose-dependent killing of melanoma cells that express IL13Rα2 and promotes T-cell activation and infiltration within the tumor microenvironment. This therapeutic modality aims to provide a **non-MHC-restricted immunotherapy option for melanoma**, particularly for patients resistant to other immune-based therapies[1][2].

Other names

IL13Rα2-CD3 bispecific T-cell engagerIL13Rα2-CD3 BTE